Fermentalg: Stable revenue and expanding sales of innovative products

Fermentalg announced revenues of €7.4 million for the first half of 2026, remaining close to the previous year's results. The company observed significant growth of 20% for its ΩRIGINS™ lipid range, primarily in high-value segments such as food supplements. This increase offset the strategic decline in aquaculture sales, which are expected to rebound thanks to higher fish oil prices.

A significant milestone is the first order for Galdieria BlueTM, a natural blue dye recognized by the US FDA and the European EFSA. Fermentalg anticipates starting industrial production in the fall of 2026. The company expects a strong second half of the year, targeting annual revenue of €20 million.